Diakonos Oncology Corp. is a clinical-stage biotechnology company dedicated to revolutionizing cancer immunotherapy with its proprietary double-loaded, patient-derived dendritic cell therapeutic platform focused on addressing the critical, unmet medical need for treatment of late-state and aggressive cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/30/25 | $20,000,000 |
Baylor College of Medicine Brain Tumor Investment Fund Buttonwood Titan QC Fund Mike Wicks | undisclosed |
